2-[4-(N-tert-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethanol | 413578-02-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-[4-(N-tert-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethanol
• 英文别名: 2-[4-(N-t-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethanol；tert-butyl N-[4-(2-hydroxyethyl)-3-[[(E)-3-(6-methoxypyridin-3-yl)prop-2-enoyl]amino]naphthalen-1-yl]carbamate
• CAS: 413578-02-6
• 化学式: C₂₆H₂₉N₃O₅
• 分子量: 463.533
• InChiKey: ORJWRJNIRUAGLG-PKNBQFBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[4-(N-tert-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethanol 在 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.0h， 生成 2-[4-(N-tert-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethyl chloride
  参考文献：
  名称：

  A Novel Class of in Vivo Active Anticancer Agents:  Achiral seco-Amino- and seco-Hydroxycyclopropylbenz[e]indolone (seco-CBI) Analogues of the Duocarmycins and CC-1065

  摘要：

  One achiral seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) (12) and seven achiral seco-amino-CBI (11a-g) analogues of CC-1065 and the duocarmycins were designed, synthesized and evaluated for their DNA-binding and anticancer properties. These compounds contain a core 2-chloroethylnaphthalene structure and they do not have a stereocenter. From thermal cleavage gel analyses, compounds 11a-g and 12 demonstrated similar covalent sequence specificity to adozelesin 3 and the racemic seco-CBI-TMI 4 for binding to the 5'-AAAAA(865)-3' site. Continuous exposure of human (K562) and murine (B16, L1210 and P815) cancer cell lines to the compounds demonstrated their significant cytotoxicity, with IC50 values in the sub-micromolar range. Generally, a good leaving group on the ethyl moiety and a free amino or hydroxyl group on the naphthyl moiety are essential for activity. According to NCI's cytotoxicity screen, compounds 11a and 12 were active against human cancer cell lines derived from lung, colon, melanoma, renal system, and breast. At the respective doses of 15 and 20 mg/kg (administered via an ip route), compounds 11a and 12 inhibited the growth of murine B16-F0 melanoma in C57BL/6 mice, with minimal toxicity, and 11a gave a significant anticancer effect. The in vivo anticancer activity of compound 11a was confirmed in a human tumor xenograft study (advanced stage SC-OVCAR-3 ovarian cancer growing in scid mice). Finally, compound 11a was not toxic to murine bone marrow cell growth in culture at a dose that was toxic for the previously reported compound 4.

  DOI：

  10.1021/jm050179u
• 作为产物：
  描述：

  氯硝萘 在 palladium on activated charcoal 吡啶 、 盐酸 、 sodium sulfide 、 氢气 、 二异丁基氢化铝 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙醇 、 乙酸乙酯 为溶剂， 20.0~60.0 ℃ 、379.21 kPa 条件下， 反应 123.5h， 生成 2-[4-(N-tert-butoxycarbonylamino)-2-(3-aza-4-methoxycinnamoylamido)naphthalen-1-yl]ethanol
  参考文献：
  名称：

  A Novel Class of in Vivo Active Anticancer Agents:  Achiral seco-Amino- and seco-Hydroxycyclopropylbenz[e]indolone (seco-CBI) Analogues of the Duocarmycins and CC-1065

  摘要：

  One achiral seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) (12) and seven achiral seco-amino-CBI (11a-g) analogues of CC-1065 and the duocarmycins were designed, synthesized and evaluated for their DNA-binding and anticancer properties. These compounds contain a core 2-chloroethylnaphthalene structure and they do not have a stereocenter. From thermal cleavage gel analyses, compounds 11a-g and 12 demonstrated similar covalent sequence specificity to adozelesin 3 and the racemic seco-CBI-TMI 4 for binding to the 5'-AAAAA(865)-3' site. Continuous exposure of human (K562) and murine (B16, L1210 and P815) cancer cell lines to the compounds demonstrated their significant cytotoxicity, with IC50 values in the sub-micromolar range. Generally, a good leaving group on the ethyl moiety and a free amino or hydroxyl group on the naphthyl moiety are essential for activity. According to NCI's cytotoxicity screen, compounds 11a and 12 were active against human cancer cell lines derived from lung, colon, melanoma, renal system, and breast. At the respective doses of 15 and 20 mg/kg (administered via an ip route), compounds 11a and 12 inhibited the growth of murine B16-F0 melanoma in C57BL/6 mice, with minimal toxicity, and 11a gave a significant anticancer effect. The in vivo anticancer activity of compound 11a was confirmed in a human tumor xenograft study (advanced stage SC-OVCAR-3 ovarian cancer growing in scid mice). Finally, compound 11a was not toxic to murine bone marrow cell growth in culture at a dose that was toxic for the previously reported compound 4.

  DOI：

  10.1021/jm050179u

文献信息

• Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins
  申请人：Taiho Pharmaceutical Co. Ltd.

  公开号：US06660742B2

  公开（公告）日：2003-12-09

  The present invention relates to novel achiral seco-analogues of DNA minor groove and sequence-selective alkylating agents (+)-CC1065 and the duocarmycins, depicted as general class I, II, III, IV and V: wherein X is a good leaving group, such as a chloride, a bromide, an iodide, a mesylate, a tosylate, an acetate, a quaternary ammonium moiety, a mercaptan, an alkylsulfoxyl, or an alkylsulfonyl group, preferably either a chloride, a bromide, or an iodide group. R1 is a suitable minor groove binding agent to enhance the interactions of the achiral seco-cyclopropaneindole (Cl) or an achiral seco-duocarmycin with specific sequences of DNA.

  该发明涉及一种新颖的DNA次级沟和序列选择性烷基化剂（+）-CC1065和duocarmycins的不对称环丙烷各向同性衍生物，表示为一般的I、II、III、IV和V类：其中X是一个良好的离去基团，如氯化物、溴化物、碘化物、甲磺酸酯、对甲苯磺酸酯、乙酸酯、季铵基团、巯基、烷基亚砜基或烷基磺酰基，最好是氯化物、溴化物或碘化物基团。R1是一个适当的次级沟结合剂，用于增强不对称环丙烷吲哚（Cl）或不对称duocarmycin与DNA特定序列的相互作用。
• A Novel Class of in Vivo Active Anticancer Agents:  Achiral <i>seco</i>-Amino- and <i>seco</i>-Hydroxycyclopropylbenz[<i>e</i>]indolone (<i>seco</i>-CBI) Analogues of the Duocarmycins and CC-1065
  作者：Atsushi Sato、LuAnne McNulty、Kari Cox、Susan Kim、Adrienne Scott、Kristen Daniell、Kaitlin Summerville、Carly Price、Stephen Hudson、Konstantinos Kiakos、John A. Hartley、Tetsuji Asao、Moses Lee

  DOI：10.1021/jm050179u

  日期：2005.6.1

  One achiral seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) (12) and seven achiral seco-amino-CBI (11a-g) analogues of CC-1065 and the duocarmycins were designed, synthesized and evaluated for their DNA-binding and anticancer properties. These compounds contain a core 2-chloroethylnaphthalene structure and they do not have a stereocenter. From thermal cleavage gel analyses, compounds 11a-g and 12 demonstrated similar covalent sequence specificity to adozelesin 3 and the racemic seco-CBI-TMI 4 for binding to the 5'-AAAAA(865)-3' site. Continuous exposure of human (K562) and murine (B16, L1210 and P815) cancer cell lines to the compounds demonstrated their significant cytotoxicity, with IC50 values in the sub-micromolar range. Generally, a good leaving group on the ethyl moiety and a free amino or hydroxyl group on the naphthyl moiety are essential for activity. According to NCI's cytotoxicity screen, compounds 11a and 12 were active against human cancer cell lines derived from lung, colon, melanoma, renal system, and breast. At the respective doses of 15 and 20 mg/kg (administered via an ip route), compounds 11a and 12 inhibited the growth of murine B16-F0 melanoma in C57BL/6 mice, with minimal toxicity, and 11a gave a significant anticancer effect. The in vivo anticancer activity of compound 11a was confirmed in a human tumor xenograft study (advanced stage SC-OVCAR-3 ovarian cancer growing in scid mice). Finally, compound 11a was not toxic to murine bone marrow cell growth in culture at a dose that was toxic for the previously reported compound 4.